Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies

Basit Öğe Kaydı
dc.contributor.authorIsik, Ahmet Feridun
dc.contributor.authorSanli, Maruf
dc.contributor.authorYilmaz, Miray
dc.contributor.authorMeteroglu, Fatih
dc.contributor.authorDikensoy, Oner
dc.contributor.authorSevinc, Alper
dc.contributor.authorCamci, Celaletdin
dc.date.accessioned2024-04-24T16:18:19Z
dc.date.available2024-04-24T16:18:19Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: Malignant pleural effusion (MPE) means poor prognosis in the majority of cases. Intrapleural Hyperthermic perfusion chemotherapy (HIPEC) looks promising approach for these patients. We aimed to investigate whether cytoreductive surgery followed by HIPEC provides any survival benefit in cases with metastatic MPEs. Methods: Between January 2009 and December 2011, 19 patients with metastatic MPEs were treated with HIPEC following surgical interventions such as pleurectomy/decortication and/or lung resection (Group 1). Comparison was done with historical control groups consisted of patients who received either talc pleurodesis or pleurectomy/decortication followed by systemic treatment for the management of metastatic MPEs between June 2007 and June 2008 (group 2 and 3). Statistical analyses including overall survival, disease free interval were done for the group comparisons. Results: Median survival in group 1, 2 and 3 were 15.4, 6, 8 months, respectively. One year survival was 54.7% in group 1 where it was 0.6% and 0.8% in group 2 and 3, respectively. There was no operative mortality. Morbidity was occurred in 1 patient in group 1 (5.3%). Conclusions: HIPEC combined with cytoreductive surgery seems to be a promising treatment option for subjects with metastatic MPEs. Further studies are needed for the optimization of HIPEC method, drug of choice, and the best combination therapy for the multimodal treatment. (C) 2013 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.rmed.2013.01.010
dc.identifier.endpage767en_US
dc.identifier.issn0954-6111
dc.identifier.issn1532-3064
dc.identifier.issue5en_US
dc.identifier.pmid23462236
dc.identifier.scopus2-s2.0-84876025076
dc.identifier.scopusqualityQ1
dc.identifier.startpage762en_US
dc.identifier.urihttps://doi.org/10.1016/j.rmed.2013.01.010
dc.identifier.urihttps://hdl.handle.net/11468/15995
dc.identifier.volume107en_US
dc.identifier.wosWOS:000318327400016
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherW B Saunders Co Ltden_US
dc.relation.ispartofRespiratory Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMalignant Pleural Effusionen_US
dc.subjectLung Carcinomaen_US
dc.subjectHyperthermic Perfusion Chemotherapyen_US
dc.titleIntrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignanciesen_US
dc.titleIntrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu